肝胆胰恶性肿瘤患者在新型冠状病毒肺炎疫情期间及疫情过后的诊治思考与建议

doi:10.11904/j.issn.1002-3070.2020.02.004

实用肿瘤学杂志 ›› 2020, Vol. 34 ›› Issue (2): 107-110.doi: 10.11904/j.issn.1002-3070.2020.02.004

肝胆胰恶性肿瘤患者在新型冠状病毒肺炎疫情期间及疫情过后的诊治思考与建议

杨磊, 苏丹综述, 娄长杰审校

哈尔滨医科大学附属肿瘤医院消化内科二病房(哈尔滨 150081)

收稿日期:2020-03-09 发布日期:2020-04-27
通讯作者: 娄长杰,E-mail:9337768@qq.com
作者简介:杨磊,女,(1995-),硕士研究生,从事消化系统肿瘤的研究。

Diagnosis and treatment of patients with hepatobiliary and pancreatic malignant tumor during and after the epidemic of corona virus disease 2019

YANG Lei, SU Dan, LOU Changjie

Department of Gastrointestinal Medical Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2020-03-09 Published:2020-04-27

摘要/Abstract

摘要： 自2019年12月底以来,新型冠状病毒肺炎(简称“新冠肺炎”)呈全球性蔓延趋势,给人类健康带来了极大的生命安全威胁。恶性肿瘤患者免疫功能低下,属于高危易感人群,一旦感染病情进展迅速。肝胆胰系统肿瘤侵袭性强、进展迅猛、预后极差、死亡率高。在严峻的疫情背景下给医患双方带来了双重的挑战,如何合理化的管控肝胆胰恶性肿瘤患者显得尤为重要。对于病情较重、有黄疸或合并胆道感染的患者应采取积极的治疗措施;而对于病情稳定、体力状态好或术后辅助治疗的患者,可以采取降低治疗强度、缩短治疗时间、延缓甚至推迟治疗的方式,具体病例临床医生应根据具体情况选择个体化治疗决策。

关键词: 新型冠状病毒肺炎, 肝胆胰腺肿瘤, 患者管理

Abstract: Since the end of December 2019,corona virus disease 2019(COVID-19)has been spreading globally,bringing great threat to human health.The patients with malignant tumors have low immune function and belong to the high risk susceptible population.Once infected,the disease progresses rapidly.Hepatocellular and pancreatic system tumors are highly invasive,progress rapidly,poor prognosis and high mortality.In the severe epidemic situation,it brings double challenges to both doctor and patient.How to rationally control the patients with hepatobiliary and pancreatic malignancies is particularly important.For patients with severe disease,jaundice or biliary tract infection should take active treatment measures,and patients with stable condition and good physical conditions or postoperative adjuvant treatment can reduce the treatment intensity and time,and delay or even postponed the treatment.The clinicians should choose the individual treatment decision based on the specific situation.

Key words: Corona virus disease 2019(COVID-19), Hepatobiliary and pancreatic cancer, Patient management

中图分类号:

R730.1

杨磊, 苏丹, 娄长杰. 肝胆胰恶性肿瘤患者在新型冠状病毒肺炎疫情期间及疫情过后的诊治思考与建议[J]. 实用肿瘤学杂志, 2020, 34(2): 107-110.

YANG Lei, SU Dan, LOU Changjie. Diagnosis and treatment of patients with hepatobiliary and pancreatic malignant tumor during and after the epidemic of corona virus disease 2019[J]. Journal of Practical Oncology, 2020, 34(2): 107-110.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.02.004

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I2/107

参考文献

1 国家卫生健康委员会,国家中医药管理局.新型冠状病毒肺炎诊疗方案(试行第六版)的通知[EB/OL].[2020-02-19].http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5474791.htm.
2 Liang WH,Guan WJ,Chen RC,et al.Cancer patients in SARS-CoV-2 infection:a nationwide analysis in China[J].Lancet Oncology,2020,21(3):335-337.
3 徐骏,耿美玉,黄敏.化疗药调控肿瘤免疫应答机制研究进展[J].药学学报,2019,54(10):1741-1748.
4 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].中国实用外科杂志,2020,40(2):121-138.
5 梁后杰,秦叔逵,沈锋,等.CSCO胆道系统肿瘤诊断治疗专家共识(2019年版)[J].临床肿瘤学杂志,2019,24(9):828-838.
6 刘梦奇,吉顺荣,徐晓武,等.2019年胰腺癌研究及诊疗新进展[J].中国癌症杂志,2020,30(1):1-10.
7 杨振宇,谭凯,杜锡林,等.新型冠状病毒疫情期间肿瘤患者的应急管理及防护措施[J].现代肿瘤医学,2020,28(6):1053-1055.
8 Vivaldi C,Fornaro L,Vasile E.FOLFIRINOX adjuvant therapy for pancreatic cancer[J].N Engl J Med,2019,380(12):1187-1188.
9 Weigt J,Malfertheiner P.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J].Eepert Rev Gastroent,2010,4(4):395-397.
10 Valle J,Wasan H,Palmer DH,et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J].N Engl J Med,2010,362(14):1273－1281.
11 Michelakos T,Pergolini I,Castillo CF,et al.Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX[J].Ann Surg,2019,269(4):733-740.
12 Okada KI,Shimokawa T,Hirono S,et al.Effect of neoadjuvant nab-paclitaxel plus gemcitabine therapy on overall survival in patients with borderline resectable pancreatic cancer:a prospective multicenter phase II Trial(NAC-GA Trial)[J].Oncology,2017,93(5):343-346.
13 Masui T,Doi R,Kawaguchi Y,et al.Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors[J].Surg Today,2016,46(11):1282-1289.
14 Kim YS,Jeong CY,Song HN,et al.The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection[J].Chin J Cancer,2017,36:1-9.
15 Uesaka K,Boku N,Fukutomi A,et al.Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer:a phase 3,open-label,randomised,non-inferiority trial(JASPAC 01)[J].Lancet,2016,388(10041):248-257.
16 Neoptolemos J,Stocken DD,Friess H,et al.A randomized trial of chemoradiotheray and chemotherapy after resection of pancreatic cancer[J].N Engl J Med,2016,350(12):1200-1210.
17 Neoptolemos JP,Palmer DH,Ghaneh P,et al.Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer(ESPAC-4):a multicentre,open-label,randomised,phase 3 trial[J].Lancet,2017,389(10073):1011-1024.
18 Conroy T,Hammel P,Hebbar M,et al.FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer[J].N Engl J Med,2018,379(25):2395-2406.
19 Rimassa L,Danesi R,Pressiani T,et al.Management of adverse events associated with tyrosine kinase inhibitors:Improving outcomes for patients with hepatocellular carcinoma[J].Cancer Treat Rev,2019,77:20-28.
20 Junki M,Chigusa M,Takuji O,et al.Randomized phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer:Japan Clinical Oncology Group Study(JCOG1113,FUGA-BT)[J].Jpn J Clin Oncol,2016,46(4):385-388.
21 Pitt HA,Gomes AS,Lois JF,et al.Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost?[J].Anna Surg,1985,201(5):545-553.
22 Nimura Y,Kamiya J,Kondo S,et al.Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma:Nagoya experience[J].J Hepatobiliary Pancreat Surg,2000,7(2):155-162.
23 易丹,杜梦楠,贾英杰.肿瘤患者在新型冠状病毒疫情期间如何规避风险[J].现代肿瘤医学,2020,28(7):1-3.

[1]	韩淑玲, 方琳, 张艳桥. 新冠肺炎疫情后肿瘤内科患者的诊疗思考[J]. 实用肿瘤学杂志, 2020, 34(2): 97-99.
[2]	刘超, 郑桐森. 新冠肺炎时期肿瘤内科工作的总结和反思[J]. 实用肿瘤学杂志, 2020, 34(2): 100-102.
[3]	马悦, 马志刚, 于杨, 郑桐森, 张艳桥, 张纯慧. 新型冠状病毒肺炎疫情期间抗肿瘤药物临床试验的管理[J]. 实用肿瘤学杂志, 2020, 34(2): 103-106.

肝胆胰恶性肿瘤患者在新型冠状病毒肺炎疫情期间及疫情过后的诊治思考与建议

Diagnosis and treatment of patients with hepatobiliary and pancreatic malignant tumor during and after the epidemic of corona virus disease 2019

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价